Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-18

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II trial studies the side effects of ex vivo-activated autologous lymph node lymphocytes infusion and to see how well they work in treating patients with chronic lymphocytic leukemia. Biological therapies, such as ex vivo-activated autologous lymph node lymphocytes, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells

NCT00224354

CHRONIC LYMPHOCYTIC B-LEUKEMIA

WITHDRAWN PHASE1

Personalized NK Cell Therapy in CBT

NCT02727803

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Acute Biphenotypic Leukemia Acute Lymphoblastic Leukemia +23 more

RECRUITING PHASE2

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

NCT03645928

Metastatic Melanoma Squamous Cell Carcinoma of the Head and Neck Non-small Cell Lung Cancer

RECRUITING PHASE2

Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

NCT00004052

Leukemia

COMPLETED PHASE2

Lymphocyte Therapy in Treating Patients With Kidney Cancer

NCT00002589

Kidney Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To assess the feasibility and safety of infusion of autologous activated T-cells (ex vivo-activated autologous lymph node lymphocytes) in patients with chronic lymphocytic leukemia.

SECONDARY OBJECTIVES:

I. To study immune reconstitution following infusion of activated T-cells in patients with chronic lymphocytic leukemia.

II. To study the incidence of infections for up to 1 year following activated T cell infusion.

III. To study the overall response rates.

OUTLINE:

Patients receive infusion of ex vivo-activated autologous lymph node lymphocytes intravenously (IV) over 10-30 minutes on day 0.

Patients who have been previously treated on study, and subsequently need additional infusions, may be retreated with previously cryopreserved expanded cells at the same or lower dose level 6-12 months after the first infusion.

After completion of study treatment, patients are followed up at 1.5 years and then every 6 months for up to 5 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia Cancer Fatigue Chronic Lymphocytic Leukemia Fever Infectious Disorder Lymphadenopathy Lymphocytosis Night Sweats Prolymphocytic Leukemia Recurrent Chronic Lymphocytic Leukemia Richter Syndrome Secondary Malignant Neoplasm Thrombocytopenia Weight Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (ex vivo autologous lymph node lymphocytes)

Patients receive infusion of ex vivo-activated autologous lymph node lymphocytes IV over 10-30 minutes on day 0.

Group Type EXPERIMENTAL

Ex Vivo-activated Autologous Lymph Node Lymphocytes

Intervention Type BIOLOGICAL

Given IV

Laboratory Biomarker Analysis

Intervention Type OTHER

Correlative studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ex Vivo-activated Autologous Lymph Node Lymphocytes

Given IV

Intervention Type BIOLOGICAL

Laboratory Biomarker Analysis

Correlative studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

X-ACT X-ACT Autologous Lymph Node Lymphocytes

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients must have a diagnosis of chronic lymphocytic leukemia (CLL) by immunophenotyping and flow cytometry analysis of blood or bone marrow

* Patients must meet criteria for treatment based on the criteria proposed by National Cancer Institute (NCI)-sponsored CLL Working Group to include at least one of the following:

* Weight loss of more than 10% over the preceding 6 months; or
* Extreme fatigue attributable to progressive disease; or
* Fever or night sweats without evidence of infection; or
* Worsening anemia (Rai stage Ill) or thrombocytopenia (Rai stage IV); or
* Massive lymphadenopathy (\> 10 cm) or rapidly progressive lymphocytosis (lymphocyte doubling time \< 6 months); or
* Prolymphocytic or Richter's transformation; or
* Patients with CLL who have received at least one prior line of therapy; or
* Patients with CLL who have frequent infections and/or recurrent secondary cancers
* No active central nervous system (CNS) disease
* All patients must have a Karnofsky performance score \> 60%
* Calculated creatinine clearance (by Cockcroft-Gault) of \> 50 ml/min
* Patients must not have untreated or uncontrolled life-threatening infection
* Patients must sign informed consent

Exclusion Criteria

* Receipt of glucocorticoids (with the exception of inhaled glucocorticoid steroids for the use of allergic rhinitis or pulmonary disease) within 2 weeks of registration
* Autoimmune disease related to CLL, e.g., idiopathic thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia, is permitted if not requiring active treatment

Eligible Sex

ALL

Accepts Healthy Volunteers

No